Friedreich Ataxia
Pipeline by Development Stage
Drug Modality Breakdown
Neurology is a $26.9B market dominated by a single blockbuster anticoagulant (ELIQUIS), representing a mature but consolidating therapeutic area.
Key Trends
- Extreme market concentration: 68% of spending driven by one FXa inhibitor product
- Psychiatric and migraine therapies emerging as secondary growth drivers
- High clinical trial activity (8,279 trials) signals continued pipeline development
Career Verdict
Neurology offers solid career stability with good hiring demand, but limited upside growth—best suited for professionals seeking established market positions rather than emerging-area innovation.
AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data
Market Leaders
| # | Product | Company | Revenue | Share | Stage | Trend | LOE |
|---|---|---|---|---|---|---|---|
| 1 | ELIQUIS (apixaban) | Bristol Myers Squibb | $18.3B | 68% | Launch | Stable | 15.0yr |
| 2 | INVEGA SUSTENNA (paliperidone palmitate) | Johnson & Johnson | $1.8B | 7% | Peak | Stable | 4.7yr |
| 3 | BRILINTA (ticagrelor) | AstraZeneca | $692M | 3% | Peak | Stable | 10.2yr |
| 4 | NUPLAZID (pimavanserin tartrate) | Acadia Pharmaceuticals | $596M | 2% | Peak | Stable | 10.9yr |
| 5 | INVEGA TRINZA (paliperidone palmitate) | Johnson & Johnson | $530M | 2% | Peak | Stable | 15.6yr |
Drug Class Breakdown
market-defining single product
stable mature class
niche but stable
specialty indication focus
emerging growth segment
stable with LOE risk
diverse small products
Career Outlook
StableNeurology represents a mature, cash-generative market with limited growth tailwinds but strong hiring stability. The dominance of ELIQUIS creates a bifurcated career landscape: high-opportunity positions in emerging segments (CGRP antagonists, psychiatric therapeutics) and commoditized roles in anticoagulant franchises. Job availability is solid but growth expectations should be tempered relative to oncology or immunology.
Breaking In
Entry-level professionals should target clinical operations or commercial support roles at J&J, AstraZeneca, or Sanofi to build domain expertise in neurology disease states and competitive dynamics.
For Experienced Professionals
Experienced professionals should prioritize emerging mechanism roles (CGRP, tau-targeting programs) or pivot to medtech/neurotech (Stryker, Medtronic) to capture higher growth and salary potential than traditional pharma incumbents.
In-Demand Skills
Best For
Hiring Landscape
Neurology shows moderate but distributed hiring across pharma and medtech employers, with 4,186 total jobs listed. Commercial functions lead (947 roles, $169K avg), followed by clinical operations (467 roles, $132K avg), indicating bias toward commercialization over R&D. Takeda leads external hiring (762 jobs) with strong representation in contract research and CRO spaces.
Top Hiring Companies
By Department
Commercial and clinical operations roles dominate, offering stable mid-career positions; engineering roles command premium salaries ($199K), suggesting strong device/neurotech hiring pockets.
Competitive Landscape
20 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
Showing 15 of 37 trials with date data
Clinical Trials (37)
Total enrollment: 6,726 patients across 37 trials
An Objective Double-blind Evaluation of Bupropion and Citalopram in an Individual With Friedreich Ataxia
A Study to Assess the Safety and Efficacy of Vatiquinone in Participants With Friedreich Ataxia
A Study to Assess the Efficacy and Safety of Vatiquinone for the Treatment of Participants With Friedreich Ataxia
An Open-Label Study of CTI-1601 in Subjects With Friedreich's Ataxia
A Study of Vatiquinone for the Treatment of Participants With Friedreich Ataxia
A Double-Blind, Placebo-Controlled, Dose Exploration Study of CTI-1601 in Adult Subjects With Friedreich's Ataxia
NAD+ Precursor Supplementation in Friedreich's Ataxia
A Clinical Study to Evaluate the Effect of MIN-102 on the Progression of Friedreich's Ataxia in Male and Female Patients
Efficacy, Tolerability, and Pharmacokinetics of Multiple Doses of Oral TAK-831 in Adults With Friedreich Ataxia
Interferon Gamma-1b in Friedreich Ataxia (FRDA)
Efficacy Study of Epoetin Alfa in Friedreich Ataxia
Efficacy of EGb761 in Patients Suffering From Friedreich Ataxia
A Multiple Ascending Dose Study of DT-216P2 in Patients With Friedreich's Ataxia
Gene Therapy for Cardiomyopathy Associated With Friedreich's Ataxia
Evaluation of the Effect of Artesunate in Friedreich Ataxia (FA)
FRDA Investigator Initiated Study (IIS) With Elamipretide
A Study of Resveratrol as Treatment for Friedreich Ataxia
A Single Ascending Dose Study of DT-216P2 in Normal Healthy Participants
A Study to Assess Nomlabofusp in Adolescents and Children With Friedreich's Ataxia
A Study of ASP2016 in Adults Who Have Heart Disease Associated With Friedreich Ataxia
Study to Evaluate Multiple Ascending Dose and Multi-Dose of DT-216 in Adult Patients With Friedreich Ataxia
Study to Evaluate DT-216 in Adult Patients With Friedreich Ataxia
Multiple Ascending Dose Study of CTI-1601 Versus Placebo in Subjects With Friedreich's Ataxia
Single Ascending Dose Study of CTI-1601 Versus Placebo in Subjects With Friedreich's Ataxia
Rosuvastatin (Crestor) in Friedreich Ataxia
Methylprednisolone Treatment of Friedreich Ataxia
A Study to Learn How BIIB141 (Omaveloxolone) Affects the Health of Participants With Friedrich's Ataxia Who Took it During Pregnancy and/or During Breastfeeding and About the Health of Their Babies
Clinical Course Of Disease In Participants With FA-CM
Understanding the Natural History Early in the Course or Presentation of Friedreich Ataxia
A Study to Learn More About the Long-Term Safety of BIIB141 (Omaveloxolone) in Participants With Friedreich's Ataxia Who Are Prescribed it by Their Own Doctors
Measurement of Frataxin mRNA in Biofluids
Friedreich Ataxia Global Clinical Consortium UNIFIED Natural History Study
Coronary Artery Disease in Patients With Friedreich's Ataxia
A Natural History Study to TRACK Brain and Spinal Cord Changes in Individuals with Friedreich Ataxia (TRACK-FA)
A Study to Assess Variation in Potential Biomarkers in Friedreich Ataxia
Neurology Measures in FA Children
FA Clinical Outcome Measures
Related Jobs in Neurology
Senior Manager, IT Security
Medical Science Liaison Lead, Riyadh, (Contract)
Contract, Formulation Development
Director of Finance, US Rare Disease
Principal Scientist, DMPK
Contract, DMPK Operations
Phase Legend
Key Insights
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.